Press Releases

ATLANTA, Ga., Dec. 9, 2019 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced the acceptance of an oral presentation at the 23rd biennial HEP DART meeting being held December 8-12, 2019 in

WASHINGTON, Dec. 9, 2019 /PRNewswire/ -- At the 2019 joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), Bruker (Nasdaq: BRKR) today announced the launch of the

LOS ANGELES, Dec. 9, 2019 /PRNewswire/ -- Joy Millan, the founder of the Southern California-based surrogate enterprise, Joy of Life, has elevated the company's mission to provide better care for surrogate mothers after giving birth to a boy recently. Summarizing the journey of her pregnancy, Joy said, "I su

Mark Zekulin to Step Down Within Current Year as Planned SMITHS FALLS, ON, Dec. 9, 2019 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) is pleased to announce that effective January 14, 2020, David Klein has b

Mark Zekulin to Step Down Within Current Year as Planned SMITHS FALLS, ON, Dec. 9, 2019 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) is pleased to announce that effective January 14, 2020, David Klein has b

NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today highlighted new data from a Phase 1 trial studying Actimab-A in combination with the salvage chemotherapy regimen CLAG-M that was presented in a poster presentation at the 61st American Society of Hematology (ASH) Annual Meeting. The

NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") presented new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) at the 2019 American Society of Hematology (ASH) annual meeting on Sunday, December 8, 2019 in a poster presentation. Actinium

OKLAHOMA CITY, Dec. 9, 2019 /PRNewswire/ -- The ranking, compiled by The Oklahoman, is based solely on employee feedback gathered through a third-party survey administered by research firm Energage

SOUTH SAN FRANCISCO, Calif., Dec. 9, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced further progress on key elements of its ongoing Phase 1/2 clinical trial entitled "A Phase 1/2 Study in Patients with Solid Tum

SEATTLE and VANCOUVER, British Columbia, Dec. 9, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced an update on the cytisinicline clinical deve